Vaxart Inc reports results for the quarter ended in September - Earnings Summary

Vaxart

02/11/2023 21:54

* Vaxart Inc  VXRT.OQ  reported a quarterly adjusted loss
of 11
cents​​ per share for the quarter ended in September, higher
than the same quarter last year, when the company reported EPS
of -23 cents.  The mean expectation of three analysts for the
quarter was for a loss of 18 cents per share. Wall Street
expected results to range from -18 cents to -17 cents per share.
    * Revenue was $2.10 million​; analysts expected $100.00
thousand. 
    * Vaxart Inc's reported EPS for the quarter was a loss of 11
cents​.
    * The company reported a quarterly loss of $17.4 million.
    * Vaxart Inc shares had fallen by 14.4% this quarter and
lost 32.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Vaxart Inc is
$4.00 
This summary was machine generated from LSEG data November 2 at
09:54 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.18          -0.11          Beat
 Jun. 30 2023      -0.18          -0.16          Beat
 Mar. 31 2023      -0.19          -0.19          Met
 Dec. 31 2022      -0.23          -0.18          Beat